GC-007g

N/A

Report date: 2024/07/03 21:31:43

Base Information

Drug NameGC-007g
Drug Alias NameDonor CAR-19Donor derived CARAnti CD19 chimeric antigen receptor T cell therapy (Gracell Biotechnology)GC007gGC-007g
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD19T lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesGracell Biotechnologies (Shanghai) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesN/A
Inactive CompaniesSuzhou Genxi Biotechnology Co LtdGracell Biotechnologies (Shanghai) Co Ltd
Active IndicationsN/A
Inactive IndicationsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A